Q1 Earnings Estimate for LENZ Issued By Leerink Partnrs

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for LENZ Therapeutics in a research report issued on Wednesday, March 19th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.53) for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2025 earnings at ($0.62) EPS and Q4 2025 earnings at ($0.83) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

LENZ has been the subject of several other research reports. TD Cowen began coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price objective for the company. Citigroup upped their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, LENZ Therapeutics has an average rating of “Buy” and an average target price of $41.67.

LENZ Therapeutics Stock Performance

NASDAQ:LENZ opened at $26.43 on Monday. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93. The company has a market cap of $726.85 million, a P/E ratio of -5.54 and a beta of 0.58. The stock’s 50-day simple moving average is $24.30 and its 200 day simple moving average is $27.12.

Institutional Investors Weigh In On LENZ Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of LENZ Therapeutics in the fourth quarter valued at about $29,000. SG Americas Securities LLC grew its stake in LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after buying an additional 935 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in LENZ Therapeutics by 14.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company’s stock valued at $229,000 after acquiring an additional 1,005 shares during the period. Rhumbline Advisers lifted its position in LENZ Therapeutics by 6.2% during the fourth quarter. Rhumbline Advisers now owns 18,754 shares of the company’s stock worth $541,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of LENZ Therapeutics by 162.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock worth $54,000 after acquiring an additional 1,151 shares during the period. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.